The anonymous blogger Chemjobber has been plying his trade as a writer for the past several years. By day, he is a process chemist at an unnamed drug/chemical manufacturer. “I'm anonymous because 'who I am' is really a distraction and it's not very interesting,” he says.
The drug industry is usually out front in assisting disaster relief, and many manufacturers have already come forth with major donations of money and supplies to Haiti in the aftermath of this week's earthquake.
Two of our favorite shows to cover during the fall conference season are the ISPE and AAPS annual meetings. Unfortunately, this year they came at exactly the same time. As ISPE kicked off earlier this week in San Diego, AAPS goers were flying into LA just up the coast.
No one is tracking pharma's social media presence better than WhyDotPharma, and the site/blog has done a nice review of which pharma companies are Twittering the most (Amgen, Boehringer, JNJ, Genentech), and how they're doing it.
While the term bailout is being tossed around liberally to suggest any government assistance in these challenging economic times, U.S. biotech leaders appear to asking for just that, or at least an indirect bailout. Members of major biotech companies and industry organization BIO will meet with Congress today to...
Once again, had to miss the best part of this presentation, but did hear Robert Bottone of Genentech discuss the problem that some managers in biopharm and pharma have with Operational Excellence. Many of them still expect “silver bullet’ solutions.
FDA issued a press release today (see below), noting that the Agency is calling for safety-related labeling changes for three biopharmaceuticals used to treat certain types of anemia. The release suggests that erythropoiesis-stimulating agents (ESAs) may pose serious health risks and have questionable efficacy in alleviating symptoms of anemia and...
Boehringer Ingelheim narrowly beat out Genentech and Amgen in Science's annual survey of top employers in the biotechnology, biopharmaceutical, pharmaceutical and related industries. The survey was based on industry responses by participants to whom they regarded as the best, average and worst employers in the field.
We'd developed an RSS feed of Bloomberg and AP clips pertinent to pharma, but let it slide a bit, due to technical issues and the fact that Bloomberg et al. didn't cover the drug industry (at least on TV) as much as they generally do, in May.